GRAIL opened lower at $152.08, compared with its previous close of $158.92. In the last trading session, the stock traded between $141.41 and $155.18. It showed a downward intraday trend.
An investment of $100 made 3 years ago in GRAIL is now worth
$ 835.71
giving a profit of
$ 735.71 (735.71%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-16.85 (-10.60%)
Day High
$155.18
Day Low
$141.41
Day Open
$152.08
Prev Close
$158.92
Volume
5,58,489
1W Return
11.65%
1M Return
3.90%
3M Return
124.01%
6M Return
185.91%
1Y Return
66.73%
Market Cap ($ Mn)
6,346
PE Ratio
-
PB Ratio
1.41
PEG Ratio
-
ROE
-16.94%
ROCE
-20.59%
EPS (TTM)
-
1 Week
11.65%
1 Month
3.90%
3 Months
124.01%
6 Months
185.91%
9 Months
40.69%
Grail to present new cancer detection data at EDCC and ESMO Congress
Grail Inc. presents six abstracts at EDCC and two at ESMO Congress in October 2026. Data from NHS-Galleri and PATHFINDER 2 studies evaluates multi-cancer early detection. Galleri test reduced Stage IV diagnoses by more than 20% after first year in some cohorts. Presentations cover health equity, rare cancer detection, and diagnostic workup efficiency.
24 days agoGuggenheim raises Grail price target to $155, maintains Buy rating
Guggenheim raised GRAIL price target from $75 to $155. Analyst Subbu Nambi maintains Buy rating on the stock. FDA panel voted 6-4 for Galleri efficacy in cancer screening. Q2FY26 revenue rose 26% YoY to $44.7 million.
29 days agoGRAIL Q2 Revenue Beats Estimates as FDA Sets Galleri PMA Review for Sept. 23
GRAIL Inc. delivered better-than-expected Q2 financials with revenue of $44.687M and a narrowed loss of $2.56 per share. Concurrently, the FDA has scheduled a Sept. 23 advisory committee meeting to review the PMA for the Galleri multi-cancer early detection test, based on data from the PATHFINDER 2 and NHS-Galleri trials.
2mo agoGrail investors urged to act by Aug 4 deadline in NHS-Galleri fraud suit
Grail, Inc. investors who bought shares between May 13, 2025, and February 19, 2026, must act by August 4, 2026, to become lead plaintiffs in a class action alleging fraud regarding the NHS-Galleri trial. The lawsuit claims executives hid internal data showing the three-year follow-up period was insufficient, leading to a 50.55% stock drop and $2.2 billion market cap loss after the trial failed to meet its primary endpoint.
2mo agoGRAIL Q2 Results: Financials due Aug 5, webcast follows
GRAIL, Inc. will report second quarter 2026 financial results after market close on Aug. 5, 2026. A management-led webcast and conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The event details are available on the company's investor relations website.
3mo agoPriority Health expands access to GRAIL's Galleri test for employers
GRAIL, Inc. partnered with Priority Health to offer the Galleri multi-cancer early detection test to self-insured employer groups, marking the first such availability in Michigan. Building on 2025 Medicare coverage, the collaboration aims to improve early detection and treatment outcomes through a simple blood draw.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 3 years ago in GRAIL is now worth
$ 835.71
giving a profit of
$ 735.71 (735.71%)
Note: Past profits do not guarantee future returns.
